Neurosense Therapeutics Ltd
Follow $NRSN
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $NRSN by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is NRSN moving today?
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
NRSN overview
Related filings and maps
Congress activity in NRSN
No receipt-qualified Congressional disclosure is present for NRSN in the cached public ledger.
NRSN contract awards, year to date.
Public federal awards linked to this ticker.
NRSN lobbying filings, year to date.
Registered lobbying filings matched to Neurosense Therapeutics Ltd.